Ozempic and Wegovy are the two brand names that Novo Nordisk uses to market injectable semaglutide.
Ozempic is used to treat type 2 diabetes and prevent major cardiovascular problems in certain patients, while Wegovy is used for chronic weight management and helps with weight loss.
The table below outlines the specific conditions that Ozempic and Wegovy are used to treat and the dosage forms and strengths each semaglutide-containing product comes in.
| Ozempic | Wegovy | |
| Generic name | Semaglutide | Semaglutide |
| Marketed by | Novo Nordisk | Novo Nordisk |
| Dosage form and strength |
Injection - 2mg/1.5mL and 2mg/3 mL
Injection - 8 mg/3mL
Dose is increased slowly up to a maximum of 2mg weekly if required. Each box comes with NovoFine Plus needles. |
Injection - pre-filled, single-dose pen delivering doses of 0.25, 0.5, 1.7 or 2.4mg).
Dose is increased slowly until a maintenance dose of 2.4mg weekly is reached |
| Uses |
|
An an add-on to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:
As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in pediatric patients aged 12 years and older with:
|
| First approved in US | 2017 | 2021 |
For more information on Wegovy, Ozempic and Rybelus, visit here: What is the difference between Wegovy, Ozempic and Rybelus?